anurajms/meta_analysis huggingface dataset:
Provide patient population that should be included in the study
Immunostimulants versus placebo for preventing exacerbations in adults with chronic bronchitis or chronic obstructive pulmonary disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Chronic Obstructive Pulmonary Disease 6. Chronic Bronchitis 7. Aged 65-79 years
Provide patient population that should be included in the study
Non‐invasive positive pressure ventilation for central sleep apnoea in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Central Sleep Apnea Syndrome 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Pulmonary rehabilitation versus usual care for adults with asthma
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Chronic Obstructive Pulmonary Disease 6. Aged 65-79 years 7. Asthma
Provide patient population that should be included in the study
Magnesium sulfate for acute exacerbations of chronic obstructive pulmonary disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. COPD Exacerbation 5. Aged 65-79 years
Provide patient population that should be included in the study
Interventions for preventing weight gain after smoking cessation
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Smoking cessation 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Non‐invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnoea
1. Erectile Dysfunction 2. Not reported 3. Obstructive Sleep Apnea Syndrome
Provide patient population that should be included in the study
Supervised maintenance programmes following pulmonary rehabilitation compared to usual care for chronic obstructive pulmonary disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Chronic Obstructive Pulmonary Disease 6. Aged 65-79 years
Provide patient population that should be included in the study
Chronic non‐invasive ventilation for chronic obstructive pulmonary disease
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Chronic Obstructive Pulmonary Disease
Provide patient population that should be included in the study
Glucocorticoid with cyclophosphamide for oral paraquat poisoning
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Pulmonary Fibrosis 6. Aged 65-79 years 7. Paraquat Toxicity
Provide patient population that should be included in the study
Combination fixed‐dose beta agonist and steroid inhaler as required for adults or children with mild asthma
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years 8. Asthma
Provide patient population that should be included in the study
Interventions for tobacco cessation delivered by dental professionals
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Smoker 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Telerehabilitation for chronic respiratory disease
1. Aged 80 and over 80+ years 2. Interstitial Lung Disease 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Idiopathic Pulmonary Fibrosis 7. Chronic Obstructive Pulmonary Disease 8. Bronchiectasis 9. Aged 65-79 years 10. Asthma
Provide patient population that should be included in the study
Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta‐analysis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Chronic Obstructive Pulmonary Disease 6. Aged 65-79 years
Provide patient population that should be included in the study
Anti‐IL‐5 therapies for chronic obstructive pulmonary disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Chronic Obstructive Pulmonary Disease 5. Aged 65-79 years
Provide patient population that should be included in the study
Proton pump inhibitors for chronic obstructive pulmonary disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Chronic Obstructive Pulmonary Disease 6. Aged 65-79 years 7. Asthma
Provide patient population that should be included in the study
Phosphodiesterase‐4 inhibitors for chronic obstructive pulmonary disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Chronic Obstructive Pulmonary Disease 6. Aged 65-79 years
Provide patient population that should be included in the study
Interventions for promoting physical activity in people with chronic obstructive pulmonary disease (COPD)
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Chronic Obstructive Pulmonary Disease 6. Aged 65-79 years
Provide patient population that should be included in the study
Educational, supportive and behavioural interventions to improve usage of continuous positive airway pressure machines in adults with obstructive sleep apnoea
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Obstructive Sleep Apnea Syndrome 6. Aged 65-79 years
Provide patient population that should be included in the study
Breathing exercises for adults with asthma
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Asthma
Provide patient population that should be included in the study
Oxygen therapy in the pre‐hospital setting for acute exacerbations of chronic obstructive pulmonary disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Chronic Obstructive Pulmonary Disease 6. COPD Exacerbation 7. Aged 65-79 years
Provide patient population that should be included in the study
Pressure modification or humidification for improving usage of continuous positive airway pressure machines in adults with obstructive sleep apnoea
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Obstructive Sleep Apnea Syndrome 6. Aged 65-79 years
Provide patient population that should be included in the study
Pharmacological agents for adults with acute respiratory distress syndrome
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Intensive Care 6. Aged 65-79 years 7. Acute Respiratory Distress Syndrome
Provide patient population that should be included in the study
Positional therapy for obstructive sleep apnoea
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Obstructive Sleep Apnea Syndrome 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Chronic Obstructive Pulmonary Disease 5. Aged 65-79 years
Provide patient population that should be included in the study
Print‐based self‐help interventions for smoking cessation
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Smoker 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD)
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Chronic Obstructive Pulmonary Disease
Provide patient population that should be included in the study
Active mind‐body movement therapies as an adjunct to or in comparison with pulmonary rehabilitation for people with chronic obstructive pulmonary disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Chronic Obstructive Pulmonary Disease 6. Aged 65-79 years
Provide patient population that should be included in the study
Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic antagonists for people with chronic obstructive pulmonary disease
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Chronic Obstructive Pulmonary Disease
Provide patient population that should be included in the study
Enhancing partner support to improve smoking cessation
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Smoker 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Nicotine replacement therapy versus control for smoking cessation
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Smoking cessation 4. Middle Aged 45-64 years 5. Smoker 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Personal Motivation 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Self‐management for bronchiectasis
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Bronchiectasis 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Family and carer smoking control programmes for reducing children's exposure to environmental tobacco smoke
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Exposed To Tobacco Smoke In Public Places 6. Middle Aged 45-64 years 7. Exposed To Tobacco Smoke At Home 8. Infant 1 to 23 mo 9. Young Adult 19-24 years 10. Birth to 1 mo 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Singing for adults with chronic obstructive pulmonary disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Chronic Obstructive Pulmonary Disease 6. Aged 65-79 years
Provide patient population that should be included in the study
Nursing interventions for smoking cessation
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Smoker 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Invasive versus non‐invasive ventilation for acute respiratory failure in neuromuscular disease and chest wall disorders
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Deformity Of Chest Wall 6. Restrictive Lung Mechanics Due To Neuromuscular Disease 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Adult 19-44 years 10. Middle Aged 45-64 years 11. Acute Respiratory Failure 12. Young Adult 19-24 years 13. Birth to 1 mo
Provide patient population that should be included in the study
Inhaled magnesium sulfate in the treatment of acute asthma
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Acute Asthma 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Mesenchymal stem cells for the prevention and treatment of bronchopulmonary dysplasia in preterm infants
1. Extremely Preterm Infant (<28 weeks) 2. Bronchopulmonary Dysplasia Of Newborn 3. Birth to 1 mo
Provide patient population that should be included in the study
Neurally adjusted ventilatory assist compared to other forms of triggered ventilation for neonatal respiratory support
1. Premature Delivery 2. Infant 1 to 23 mo 3. Birth to 1 mo 4. Mechanical ventilation
Provide patient population that should be included in the study
Inhaled versus systemic corticosteroids for preventing bronchopulmonary dysplasia in ventilated very low birth weight preterm neonates
1. Very Preterm Infant (28-31 weeks) 2. Extremely Preterm Infant (<28 weeks) 3. Birth to 1 mo 4. Very Low Birth Weight Infant 5. Mechanical ventilation
Provide patient population that should be included in the study
Inhaled versus systemic corticosteroids for the treatment of bronchopulmonary dysplasia in ventilated very low birth weight preterm infants
1. Very Preterm Infant (28-31 weeks) 2. Extremely Preterm Infant (<28 weeks) 3. Dependence On Ventilator 4. Birth to 1 mo 5. Very Low Birth Weight Infant
Provide patient population that should be included in the study
Shared decision‐making for people with asthma
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Asthma
Provide patient population that should be included in the study
Positive expiratory pressure therapy versus other airway clearance techniques for bronchiectasis
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Bronchiectasis 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Asthma
Provide patient population that should be included in the study
Culture‐specific programs for children and adults from minority groups who have asthma
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Ethnic Group 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Adolescent 13-18 years 10. Asthma
Provide patient population that should be included in the study
Aerosolized prostacyclins for acute respiratory distress syndrome (ARDS)
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Acute Respiratory Distress Syndrome 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Self‐management interventions including action plans for exacerbations versus usual care in patients with chronic obstructive pulmonary disease
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Chronic Obstructive Pulmonary Disease
Provide patient population that should be included in the study
ProSeal versus Classic laryngeal mask airway (LMA) for positive pressure ventilation in adults undergoing elective surgery
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Elective Surgery 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. General Anesthesia 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Non‐invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Acute Respiratory Failure 4. Young Adult 19-24 years 5. COPD Exacerbation
Provide patient population that should be included in the study
Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD)
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Chronic Obstructive Pulmonary Disease
Provide patient population that should be included in the study
Mass media interventions for preventing smoking in young people
1. Child 6-12 years 2. Tobacco Smoking Behavior 3. Young Adult 19-24 years 4. Adolescent 13-18 years
Provide patient population that should be included in the study
Computer and mobile technology interventions for self‐management in chronic obstructive pulmonary disease
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Chronic Obstructive Pulmonary Disease
Provide patient population that should be included in the study
Tobacco packaging design for reducing tobacco use
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Smoker 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Lay‐led and peer support interventions for adolescents with asthma
1. Child 6-12 years 2. Young Adult 19-24 years 3. Adolescent 13-18 years 4. Asthma
Provide patient population that should be included in the study
Interventions to improve adherence to inhaled steroids for asthma
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Asthma
Provide patient population that should be included in the study
Asthma education for school staff
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Adolescent 13-18 years 4. Asthma
Provide patient population that should be included in the study
Group behaviour therapy programmes for smoking cessation
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Smoker 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Psychological therapies for the treatment of anxiety disorders in chronic obstructive pulmonary disease
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Anxiety Disorder 4. Chronic Obstructive Pulmonary Disease 5. Anxiety Symptoms
Provide patient population that should be included in the study
Addition of anti‐leukotriene agents to inhaled corticosteroids for adults and adolescents with persistent asthma
1. Adult 19-44 years 2. Child 6-12 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Adolescent 13-18 years 6. Asthma
Provide patient population that should be included in the study
Interventions to improve inhaler technique for people with asthma
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Asthma
Provide patient population that should be included in the study
System change interventions for smoking cessation
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Smoker 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Fluid restriction for treatment of preterm infants with chronic lung disease
1. Very Preterm Infant (28-31 weeks) 2. Moderate Preterm Infant (32-33 weeks) 3. Extremely Preterm Infant (<28 weeks) 4. Bronchopulmonary Dysplasia Of Newborn 5. Birth to 1 mo
Provide patient population that should be included in the study
Stepping down the dose of inhaled corticosteroids for adults with asthma
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Asthma
Provide patient population that should be included in the study
Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Chronic Obstructive Pulmonary Disease
Provide patient population that should be included in the study
Combined inhaled beta‐agonist and anticholinergic agents for emergency management in adults with asthma
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Emergency Care 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Asthma exacerbation 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Asthma
Provide patient population that should be included in the study
Action plans with brief patient education for exacerbations in chronic obstructive pulmonary disease
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Chronic Obstructive Pulmonary Disease 4. Aged 65-79 years
Provide patient population that should be included in the study
Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Chronic Obstructive Pulmonary Disease 6. COPD Exacerbation 7. Aged 65-79 years
Provide patient population that should be included in the study
Oxygen for breathlessness in patients with chronic obstructive pulmonary disease who do not qualify for home oxygen therapy
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Hypoxemia 5. Young Adult 19-24 years 6. Chronic Obstructive Pulmonary Disease 7. Aged 65-79 years
Provide patient population that should be included in the study
Upper limb exercise training for COPD
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Chronic Obstructive Pulmonary Disease
Provide patient population that should be included in the study
Exhaled nitric oxide levels to guide treatment for children with asthma
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Adolescent 13-18 years 4. Asthma
Provide patient population that should be included in the study
Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Chronic Obstructive Pulmonary Disease 5. COPD Exacerbation
Provide patient population that should be included in the study
Smoking cessation for people with chronic obstructive pulmonary disease
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Smoker 4. Young Adult 19-24 years 5. Chronic Obstructive Pulmonary Disease
Provide patient population that should be included in the study
Endothelin receptor antagonists for persistent pulmonary hypertension in term and late preterm infants
1. Persistent Pulmonary Hypertension Of The Newborn 2. Post-term Infant - 42 Weeks Plus 3. Term infant (37-41 weeks) 4. Birth to 1 mo 5. Late Preterm Infant (34-36 weeks)
Provide patient population that should be included in the study
Home telemonitoring and remote feedback between clinic visits for asthma
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Asthma
Provide patient population that should be included in the study
Guanylate cyclase stimulators for pulmonary hypertension
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Pulmonary Hypertension 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Codeine versus placebo for chronic cough in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Chronic Cough 4. Infant 1 to 23 mo 5. Birth to 1 mo 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Ambulatory and short‐burst oxygen for interstitial lung disease
1. Aged 80 and over 80+ years 2. Interstitial Lung Disease 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Exertional Oxygen Desaturation 7. Aged 65-79 years
Provide patient population that should be included in the study
Combination inhaled steroid and long‐acting beta2‐agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Chronic Obstructive Pulmonary Disease
Provide patient population that should be included in the study
Different oral corticosteroid regimens for acute asthma
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Acute Asthma 6. Young Adult 19-24 years 7. Adolescent 13-18 years 8. Asthma
Provide patient population that should be included in the study
Intravenous magnesium sulfate for treating children with acute asthma in the emergency department
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Acute Asthma 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Remote versus face‐to‐face check‐ups for asthma
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Asthma
Provide patient population that should be included in the study
Breathing exercises for children with asthma
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Adolescent 13-18 years 4. Asthma
Provide patient population that should be included in the study
High‐frequency oscillatory ventilation versus conventional ventilation for acute respiratory distress syndrome
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Mechanical ventilation 9. Aged 65-79 years 10. Acute Respiratory Distress Syndrome 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Combined pharmacotherapy and behavioural interventions for smoking cessation
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Smoker 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Protocolized versus non‐protocolized weaning for reducing the duration of invasive mechanical ventilation in newborn infants
1. Term infant (37-41 weeks) 2. Birth to 1 mo 3. Preterm Infant 4. Mechanical ventilation
Provide patient population that should be included in the study
Smoking cessation advice for people with serious mental illness
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Severe mental disorder 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Inhaled non‐steroid anti‐inflammatories for children and adults with bronchiectasis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Bronchiectasis 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Long‐acting muscarinic antagonists (LAMA) added to combination long‐acting beta2‐agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Asthma
Provide patient population that should be included in the study
Comparison of animal‐derived surfactants for the prevention and treatment of respiratory distress syndrome in preterm infants
1. Very Preterm Infant (28-31 weeks) 2. Extremely Preterm Infant (<28 weeks) 3. Birth to 1 mo 4. Neonatal Respiratory Distress Syndrome 5. Preterm Infant 6. Mechanical ventilation
Provide patient population that should be included in the study
Addition of long‐acting beta2‐agonists to inhaled corticosteroids for chronic asthma in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Adolescent 13-18 years 4. Asthma
Provide patient population that should be included in the study
Airway clearance techniques for bronchiectasis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Bronchiectasis 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for enhancing adherence to treatment in adults with bronchiectasis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Bronchiectasis 6. Aged 65-79 years
Provide patient population that should be included in the study
Exercise training to improve exercise capacity and quality of life in people with non‐malignant dust‐related respiratory diseases
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Dust-related respiratory disease 6. Aged 65-79 years
Provide patient population that should be included in the study
Interventions for smokeless tobacco use cessation
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Smoker 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Long‐acting beta2‐agonist in addition to tiotropium versus either tiotropium or long‐acting beta2‐agonist alone for chronic obstructive pulmonary disease
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Chronic Obstructive Pulmonary Disease
Provide patient population that should be included in the study
Leukotriene receptor antagonists as maintenance and intermittent therapy for episodic viral wheeze in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Wheezing
Provide patient population that should be included in the study
Tonsillectomy or adenotonsillectomy versus non‐surgical management for obstructive sleep‐disordered breathing in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Breathing-related Sleep Disorder 4. Adolescent 13-18 years
Provide patient population that should be included in the study
Calcium channel blockers for pulmonary arterial hypertension
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Pulmonary Arterial Hypertension 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Chronic Obstructive Pulmonary Disease
Provide patient population that should be included in the study
Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with asthma
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Asthma
Provide patient population that should be included in the study
Animal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndrome
1. Birth to 1 mo 2. Neonatal Respiratory Distress Syndrome 3. Preterm Infant
Provide patient population that should be included in the study
Prolonged antibiotics for non‐cystic fibrosis bronchiectasis in children and adults
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Bronchiectasis 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Intermittent inhaled corticosteroid therapy versus placebo for persistent asthma in children and adults
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Adolescent 13-18 years 10. Asthma
Provide patient population that should be included in the study
Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Asthma
Provide patient population that should be included in the study
Effects of opioid, hypnotic and sedating medications on sleep‐disordered breathing in adults with obstructive sleep apnoea
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Obstructive Sleep Apnea Syndrome 6. Aged 65-79 years
Provide patient population that should be included in the study
Stopping long‐acting beta2‐agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Asthma
Provide patient population that should be included in the study
Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long‐acting beta2‐agonists (LABA) for adults with asthma
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Asthma
Provide patient population that should be included in the study
Stopping long‐acting beta2‐agonists (LABA) for children with asthma well controlled on LABA and inhaled corticosteroids
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Adolescent 13-18 years 4. Asthma
Provide patient population that should be included in the study
Pulmonary rehabilitation for chronic obstructive pulmonary disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Chronic Obstructive Pulmonary Disease 6. Aged 65-79 years
Provide patient population that should be included in the study
Pressure‐controlled versus volume‐controlled ventilation for acute respiratory failure due to acute lung injury (ALI) or acute respiratory distress syndrome (ARDS)
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Invasive Mechanical Ventilation 4. Middle Aged 45-64 years 5. Acute Respiratory Failure 6. Young Adult 19-24 years 7. Intensive Care 8. Aged 65-79 years 9. Acute Lung Injury 10. Acute Respiratory Distress Syndrome
Provide patient population that should be included in the study
Early versus late tracheostomy for critically ill patients
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Critical Illness 6. Mechanical ventilation 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Indacaterol, a once‐daily beta2‐agonist, versus twice‐daily beta2‐agonists or placebo for chronic obstructive pulmonary disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Chronic Obstructive Pulmonary Disease 6. Aged 65-79 years
Provide patient population that should be included in the study
Alpha‐2 agonists for long‐term sedation during mechanical ventilation in critically ill patients
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Invasive Mechanical Ventilation 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Intensive Care 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Pentoxifylline for the prevention of bronchopulmonary dysplasia in preterm infants
1. Very Preterm Infant (28-31 weeks) 2. Extremely Preterm Infant (<28 weeks) 3. Continuous Positive Airway Pressure Ventilation 4. Birth to 1 mo 5. Very Low Birth Weight Infant 6. Mechanical ventilation 7. Oxygen Supplementation
Provide patient population that should be included in the study
Aclidinium bromide for stable chronic obstructive pulmonary disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Chronic Obstructive Pulmonary Disease 6. Aged 65-79 years
Provide patient population that should be included in the study
Automated weaning and SBT systems versus non‐automated weaning strategies for weaning time in invasively ventilated critically ill adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Invasive Mechanical Ventilation 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Critical Illness 7. Aged 65-79 years
Provide patient population that should be included in the study
Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Chronic Obstructive Pulmonary Disease 6. COPD Exacerbation 7. Aged 65-79 years
Provide patient population that should be included in the study
Continuous positive airway pressure (CPAP) during the postoperative period for prevention of postoperative morbidity and mortality following major abdominal surgery
1. Aged 80 and over 80+ years 2. Abdominal surgery 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Postoperative State 7. Aged 65-79 years
Provide patient population that should be included in the study
Inhaled anticholinergics and short‐acting beta2‐agonists versus short‐acting beta2‐agonists alone for children with acute asthma in hospital
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Acute Asthma 5. Hospitalization 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Tiotropium versus placebo for chronic obstructive pulmonary disease
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Chronic Obstructive Pulmonary Disease
Provide patient population that should be included in the study
Water‐based exercise for adults with asthma
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Asthma
Provide patient population that should be included in the study
Inhaled corticosteroids in children with persistent asthma: effects on growth
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Birth to 1 mo 5. Adolescent 13-18 years 6. Asthma
Provide patient population that should be included in the study
Inhaled corticosteroids in children with persistent asthma: dose‐response effects on growth
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Adolescent 13-18 years 5. Asthma
Provide patient population that should be included in the study
Ambulatory oxygen for people with chronic obstructive pulmonary disease who are not hypoxaemic at rest
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Chronic Obstructive Pulmonary Disease 6. Aged 65-79 years
Provide patient population that should be included in the study
Combination inhaled corticosteroids and long‐acting beta2‐agonists for children and adults with bronchiectasis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Bronchiectasis 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Acute Asthma 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Written emotional disclosure for asthma
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Asthma
Provide patient population that should be included in the study
Non‐invasive ventilation during exercise training for people with chronic obstructive pulmonary disease
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Chronic Obstructive Pulmonary Disease
Provide patient population that should be included in the study
Mucolytics for bronchiectasis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Bronchiectasis 6. Aged 65-79 years
Provide patient population that should be included in the study
Long‐acting inhaled therapy (beta‐agonists, anticholinergics and steroids) for COPD: a network meta‐analysis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Chronic Obstructive Pulmonary Disease 6. Aged 65-79 years
Provide patient population that should be included in the study
Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Chronic Obstructive Pulmonary Disease 6. Aged 65-79 years
Provide patient population that should be included in the study
Addition to inhaled corticosteroids of long‐acting beta2‐agonists versus anti‐leukotrienes for chronic asthma
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Asthma
Provide patient population that should be included in the study
Water‐based exercise training for chronic obstructive pulmonary disease
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Chronic Obstructive Pulmonary Disease
Provide patient population that should be included in the study
Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Asthma
Provide patient population that should be included in the study
Noninvasive positive‐pressure ventilation as a weaning strategy for intubated adults with respiratory failure
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Invasive Mechanical Ventilation 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Intubation 7. Respiratory Failure 8. Aged 65-79 years
Provide patient population that should be included in the study
Antibody induction therapy for lung transplant recipients
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Transplant Of Lung 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Smartphone and tablet self management apps for asthma
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Asthma
Provide patient population that should be included in the study
Thyrotropin‐releasing hormone added to corticosteroids for women at risk of preterm birth for preventing neonatal respiratory disease
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Pregnancy 5. Threatened Premature Labor - Not Delivered 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Prostaglandins before caesarean section for preventing neonatal respiratory distress
1. Adult 19-44 years 2. Cesarean Section 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Pregnancy 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus placebo for chronic obstructive pulmonary disease
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Chronic Obstructive Pulmonary Disease
Provide patient population that should be included in the study
Long‐acting beta2‐agonists for chronic obstructive pulmonary disease
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Chronic Obstructive Pulmonary Disease
Provide patient population that should be included in the study
Beclometasone for chronic obstructive pulmonary disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Chronic Obstructive Pulmonary Disease 5. Aged 65-79 years
Provide patient population that should be included in the study
Addition of anti‐leukotriene agents to inhaled corticosteroids in children with persistent asthma
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Adolescent 13-18 years 5. Asthma
Provide patient population that should be included in the study
Beta2‐agonists for exercise‐induced asthma
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Exercise-induced Asthma 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Physical training for asthma
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years 8. Asthma
Provide patient population that should be included in the study
Holding chambers (spacers) versus nebulisers for beta‐agonist treatment of acute asthma
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Acute Asthma 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Inspiratory muscle training for asthma
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Asthma
Provide patient population that should be included in the study
Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Chronic Obstructive Pulmonary Disease
Provide patient population that should be included in the study
Combined inhaled anticholinergics and short‐acting beta2‐agonists for initial treatment of acute asthma in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Acute Asthma 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Partial liquid ventilation for preventing death and morbidity in adults with acute lung injury and acute respiratory distress syndrome
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Mechanical ventilation 6. Aged 65-79 years 7. Acute Lung Injury 8. Acute Respiratory Distress Syndrome 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Combination inhaled steroid and long‐acting beta2‐agonist versus tiotropium for chronic obstructive pulmonary disease
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Chronic Obstructive Pulmonary Disease 5. Aged 65-79 years
Provide patient population that should be included in the study
Drug therapy for obstructive sleep apnoea in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Obstructive Sleep Apnea Syndrome 6. Aged 65-79 years
Provide patient population that should be included in the study
Physician advice for smoking cessation
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Smoker 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years